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TO THE EDITOR
Recently, we read with interest the
article titled ‘‘IL-18 downregulates
collagen production in human dermal
fibroblasts via the ERK pathway’’. In this
article, Kim et al. (2010) reported that
IL-18 downregulates collagen produc-
tion in human dermal fibroblasts
directly via the E26 transformation-
specific-1 and the ERK pathway,
suggesting that IL-18 may exert anti-
fibrotic activities in dermal fibroblasts
from patients with systemic sclerosis
(SSc). On the basis of these results,
the authors concluded that IL-18 may
represent a class of modulators
with potential usefulness in treating
excessive fibrosis in skin.
However, an earlier study by
Mosaad et al. (2003) found that serum
IL-18 levels in SSc patients were sig-
nificantly higher than that in a control
group, and there was a significant
positive correlation between the levels
of IL-18 and clinical grades of SSc.
Moreover, a study carried out by Scala
et al. (2004) found that IL-18 in
supernatants from phytohaemagglutinin-
stimulated peripheral blood mononu-
clear cells was increased in SSc patients,
and IL-18 production from peripheral
blood mononuclear cells was related
to kidney involvement. These studies
suggest that elevations in the proinflam-
matory cytokine IL-18 may trigger
inflammation in SSc, as IL-18 levels are
correlated with disease activity.
As described above, studies on the
role of IL-18 in SSc seem to be contra-
dictory. In fact, Kim et al. (2010)
discussed in their article that IL-18 has
multiple functions and that it partici-
pates in both Th1- and Th2-mediated
responses. Working in different sys-
tems, Zhang et al. (2007) have reported
that hepatic fibrosis is exacerbated by
IL-18, which activates CD4þ T cells,
and that this effect is blocked by anti-
IL-18 treatment Reddy et al. (2008).
Moreover, Reddy et al. (2008) reported
that IL-18 upregulates fibronectin ex-
pression in primary human cardiac
fibroblasts. Therefore, IL-18 may also
be regarded as a fibrogenic cytokine.
By contrast, there is additional
evidence suggesting that IL-18 can also
inhibit fibrosis. Nakatani-Okuda et al.
(2005) have reported that IL-18 has a
crucial role in protection against bleo-
mycin-induced lung injuries in mice.
Zhang et al. (2001) found that IL-18
reverses hepatic fibrosis and regulates
Th1 and Th2 cytokine responses.
In summary, IL-18 seems to function
both as a profibrotic and antifibrotic
mediator of fibrosis, which may depend
on the induction of Th1 or Th2 cytokine
profiles. We would submit that it is still
too early to say that IL-18 can induce
SSc or benefit SSc. Additional studies
with more patients and animal studies,
as well, will be needed to determine the
precise roles of IL-18 in SSc. Unraveling
the relationship between IL-18 produc-
tion and the activity of SSc may then
allow the identification of relevant
targets for therapeutic intervention.
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Abbreviations: ERK, extracellular signal-regulated protein kinase; Ets-1, E26 transformation-specific-1;
HDF, human dermal fibroblast; IL-18, interleukin-18; PBMC, peripheral blood mononuclear cell; PHA,
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